UBS AM’s Kronos Bio KRON Stock Holding History

UBS AM’s Portfolio KRON Stock Details KRON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-142,749	Closed	-$2.99M	–	2881
2021 Q3	$2.99M	Sell	142,749 -3,457	-2%	-$74.3K	﹤0.01%	1641
2021 Q2	$3.5M	Sell	146,206 -5,428	-4%	-$137K	﹤0.01%	1562
2021 Q1	$4.44M	Buy	+151,634	New	+$4.44M	﹤0.01%	1391

Other funds holding KRON

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VVA

Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS AM's KRON Position: Q4 2021 in Review

UBS AM sold out of Kronos Bio (KRON) in Q4 2021, closing a stake of 142,749 shares — an estimated $2.99M sold.

UBS AM first reported a position in KRON in Q1 2021 and held it in 3 quarters. The position peaked at $4.44M in Q1 2021. 81 funds tracked by Wall St. Rank hold KRON as of Q4 2021.

UBS AM reported no remaining Kronos Bio position as of Q4 2021 after selling out during the quarter.
UBS AM sold 142,749 Kronos Bio shares in Q4 2021, an estimated $2.99M.
UBS AM first reported a position in Kronos Bio in Q1 2021 and held it in 3 quarters.
UBS AM's Kronos Bio position peaked at $4.44M in Q1 2021.
81 funds tracked by Wall St. Rank held Kronos Bio as of Q4 2021.

Based on UBS AM's 13F filing for Q4 2021, filed 14 Feb 2022.